id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0118-0007,FDA,FDA-2016-E-0118,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-01-29T05:00:00Z,2018,1,2018-01-29T05:00:00Z,,2018-01-29T20:50:17Z,,0,0,0900006482e7a1db
FDA-2016-E-0118-0006,FDA,FDA-2016-E-0118,Determinations of Regulatory Review Periods for Purpose of Patent Extensions: NATPARA,Notice,Determinations,2017-06-15T04:00:00Z,2017,6,2017-06-15T04:00:00Z,2017-08-15T03:59:59Z,2017-06-15T13:42:11Z,2017-12359,0,0,09000064826dbb91
FDA-2016-E-0118-0005,FDA,FDA-2016-E-0118,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-07T04:00:00Z,2017,6,2017-06-07T04:00:00Z,,2017-06-07T15:32:18Z,,0,0,09000064826a1cb2
FDA-2016-E-0118-0004,FDA,FDA-2016-E-0118,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T16:26:39Z,,0,0,090000648243436b
FDA-2016-E-0118-0003,FDA,FDA-2016-E-0118,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-03-16T04:00:00Z,2016,3,2016-03-16T04:00:00Z,,2016-03-16T19:18:40Z,,0,0,0900006481ec480c
FDA-2016-E-0118-0001,FDA,FDA-2016-E-0118,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-01-11T05:00:00Z,2016,1,2016-01-11T05:00:00Z,,2016-01-11T18:58:13Z,,0,0,0900006481dfdfbf
FDA-2016-E-0118-0002,FDA,FDA-2016-E-0118,Patent Term Extension Application from Stoel Rives LLP on behalf of NPS Pharmaceuticals Inc.,Other,Application,2016-01-11T05:00:00Z,2016,1,2016-01-11T05:00:00Z,,2016-01-11T19:00:12Z,,0,0,0900006481dfdfc0